Molecular Pathology in Cancer Research
110,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 6-10 Tagen
payback
55 °P sammeln
  • Gebundenes Buch

The aim of the book is to discuss the application of molecular pathology in cancer research, and its contribution in the classification of different tumors and identification of potential molecular targets, as well as how this knowledge may be translated into clinical practice, and the huge impact this field is likely to have in the next 5 to 10 years.

Andere Kunden interessierten sich auch für
Produktbeschreibung
The aim of the book is to discuss the application of molecular pathology in cancer research, and its contribution in the classification of different tumors and identification of potential molecular targets, as well as how this knowledge may be translated into clinical practice, and the huge impact this field is likely to have in the next 5 to 10 years.
Autorenporträt
Sunil Lakhani is State Director, Anatomical Pathology, Pathology Queensland, Professor and Head, Molecular & Cellular Pathology, The School of Medicine, and Head of the Breast Group, The University of Queensland Centre for Clinical Research (UQCCR). His research team comprises scientists and practicing clinicians ensuring a translational focus to the research portfolio. His current research interests include lobular carcinoma and its variants, tumours with a basal phenotype and mechanisms of brain and distant metastases. He is a series editor for the WHO Tumour Classification Books and volume editor for the WHO Classification Tumours of the Breast (4th Ed 2012). Stephen Fox is Director of Pathology at the Peter MacCallum Cancer Centre, Professorial Fellow at the University of Melbourne and an NH&MRC Practitioner Fellow. His research has primarily been aimed at understanding the molecular basis of cancer, with emphasis on prognosis and predictive markers of human tumours with more recent work focusing on developing and implementing clinical grade diagnostics, particularly in sequencing to match the new paradigm of personalised medicine.